|
[1]
|
Walker CH, Hopkin SP, Sibly RM, et al. National Research Council. Committee on biological markers[J]. Environ Health Persp,1987, 74:3. |
|
[2]
|
Liu RZ, Li XD, Godbout R. A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis[J]. Genomics, 2008, 92: 436. |
|
[3]
|
Vreugdenhil A, Wolters VM, Van den Neucker A, et al. 193 Enhanced I-FABP levels in children with celiac disease rapidly recover aAfter gluten free diet. Potential marker for diagnosis and follow-up of celiac disease[J]. Gastroenterology, 2009, 136: A36. |
|
[4]
|
Luk GD, Vaughan WP, Burke PJ, et al. Diamine oxidase as a plasma marker of rat intestinal mucosaln injury and regeneration after administration of 1-β-d-arabinofuranosylcytosine[J]. Cancer Res,1981, 41:2334. |
|
[5]
|
Kenji M, Yasuhide K, Hidenobu M, et al. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral uorouracil anti-cancer drugs[J]. Toxicology, 2006, 217:23. |
|
[6]
|
Huang JS, Chuang LY, Gu JY. Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells[J]. Toxical Appl Pharm, 2008,233: 220. |
|
[7]
|
Ghandforoush-Sattari M, Mashayekh S. Evaluation of taurine as a biomarker of liver damage in paracetamol poisoning[J]. Eur J Pharmacol, 2008, 581:171. |
|
[8]
|
Ramaiah SK. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters[J]. Toxicology. 2007, 45: 1551. |
|
[9]
|
Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity[J]. Toxicology, 2008, 245: 194. |
|
[10]
|
Allen C, Abdolsamad B, Philip M, et al. Hydrolysis of pyrethroids by human and rat tissues: Examination of intestinal liver and serum carboxylesterases[J]. Toxicol Appl Pharm, 2007, 221: 1. |
|
[11]
|
Gressner S, Jafari ME, Frank Y, et al. Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease[J]. Clin Chim Acta, 2009, 403:188. |
|
[12]
|
蒋 莹, 阿依吐拉. 转化生长因子β1和基质金属蛋白酶抑制因子β1在肝硬化组织中的表达及其临床意义[J]. 临床肝胆病杂志, 2009,25:39. |
|
[13]
|
Duller P, Stiegler M, Schweiger T, et al. Sensitive serum parameters for hepatocellular carcinoma recurrence monitoring after liver transplantation: A case report[J]. Transpl P, 2007, 39:3281. |
|
[14]
|
Takayama R, Nakagawa H, Sawaki A, et al. Serum tumor antigen Reg4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma[J]. Gastroenterology, 2008, 134: A695. |
|
[15]
|
Salama I, Malone PS, Mihaimeed F. A review of the S100 proteins in cancer[J]. Eur J Surg Onc, 2008, 34:357. |
|
[16]
|
Oliveira-Cunha M, Siriwardena AK, Byers R. Molecular diagnosis in pancreatic cancer[J]. Diagn Hist, 2008, 14:214-222. |
|
[17]
|
Kacira T, Hanimoglu H, Kucur M, et al. Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage[J]. J Clin Neurosci, 2008,15:1011. |
|
[18]
|
Scheer M, Wild S, Kuebler AC, et al. YKL-40 as prognostic biomarker in patients with oral cancer[J]. J Cranio Maxill Surg, 2008, 36: S190. |
|
[19]
|
Jain KK. The Handbook of Biomarkers[M]. New York: Humana Press, 2010:1-84. |
|
[20]
|
Azuaje F. Bioinformatics and Biomarker Discovery [M]. Chichester: Wiley-Blackwell, 2010:173. |
点击查看大图
下载:
